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Abstract 
This report describes the production and certification of ERM-DA476/IFCC, a new serum protein reference material intended for the standardisation of 
measurements of anti-myeloperoxidase immunoglobulin G (anti-MPO IgG) antibodies. The material was produced according to ISO Guide 34:2009 . 
The raw material used to prepare ERM-DA476/IFCC was a plasmapheresis material containing a high concentration of anti-MPO IgG. After a thorough 
commutability study lyophilised serum was selected as the format for the candidate reference material. Serum processing was performed based on 
the procedure used for the reference material ERM-DA470k/IFCC . The plasma was converted into serum which was then delipidated. After the 
addition of preservatives the processed serum was diluted with plasmapheresis solution containing albumin, prior to the transfer of 1 mL aliquots to 
glass vials. The serum was then lyophilised and the vials closed with rubber stoppers and screw caps under nitrogen atmosphere prior to storage at -
70 °C.  
The between unit-homogeneity was quantified and stability during dispatch and storage were assessed in accordance with ISO Guide 35:2006.  
The material was characterised by an inter-laboratory comparison exercise performed by laboratories of demonstrated competence and with 
adherence to ISO/IEC 17025, using a purified anti-MPO IgG preparation as calibrant. This was achieved using a value transfer protocol previously used 
in the characterisation of ERM-DA470k/IFCC [3]. Technically invalid results were removed. However no other outliers were eliminated on statistical 
grounds only.  
Uncertainties of the certified values were calculated in accordance to the Guide to the Expression of Uncertainty in Measurement (GUM) and include 
uncertainties relating to possible lack of homogeneity, instability and characterisation. 
The material is intended for the calibration of methods and quality control. As any reference material, it can also be used for control charts or 
validation studies. The CRM is available in glass vials containing the lyophilised residue of 1 g serum. The minimum amount of reconstituted sample 
to be used is 10 µL. 
The CRM was accepted as European Reference Material (ERM®) after peer evaluation by the partners of the European Reference Materials consortium.
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Summary 
This report describes the production and certification of ERM-DA476/IFCC, a new serum 
protein reference material intended for the standardisation of measurements of anti-
myeloperoxidase immunoglobulin G (anti-MPO IgG) antibodies. The material was produced 
according to ISO Guide 34:2009 [1]. 
The raw material used to prepare ERM-DA476/IFCC was a plasmapheresis material 
containing a high concentration of anti-MPO IgG. After a thorough commutability study 
lyophilised serum was selected as the format for the candidate reference material [2]. Serum 
processing was performed based on the procedure used for the reference material ERM-
DA470k/IFCC [3]. The plasma was converted into serum which was then delipidated. After 
the addition of preservatives the processed serum was diluted with plasmapheresis solution 
containing albumin, prior to the transfer of 1 mL aliquots to glass vials. The serum was then 
lyophilised and the vials closed with rubber stoppers and screw caps under nitrogen 
atmosphere prior to storage at -70 °C.  
The between unit-homogeneity was quantified and stability during dispatch and storage were 
assessed in accordance with ISO Guide 35:2006 [4].  
The material was characterised by an inter-laboratory comparison exercise performed by 
laboratories of demonstrated competence and with adherence to ISO/IEC 17025 [5], using a 
purified anti-MPO IgG preparation as calibrant. This was achieved using a value transfer 
protocol previously used in the characterisation of ERM-DA470k/IFCC [3]. Technically invalid 
results were removed. However no other outliers were eliminated on statistical grounds only.  
Uncertainties of the certified values were calculated in accordance to the Guide to the 
Expression of Uncertainty in Measurement (GUM) [6] and include uncertainties relating to 
possible lack of homogeneity, instability and characterisation. 
The material is intended for the calibration of methods and quality control. As any reference 
material, it can also be used for control charts or validation studies. The CRM is available in 
glass vials containing the lyophilised residue of 1 g serum. The minimum amount of 
reconstituted sample to be used is 10 µL. 
The CRM was accepted as European Reference Material (ERM®) after peer evaluation by 
the partners of the European Reference Materials consortium. 
The following value was assigned: 
 
Mass Concentration  
Certified value 2) 
[mg/L] 
Uncertainty 3) 
[mg/L] 
anti-MPO IgG1) 84 9 
1) Anti-myeloperoxidase immunoglobulin G as measured by immunoassays 
2) Unweighted mean value of the means of accepted data sets each set obtained in a different laboratory and/or with 
a different method of determination. The certified mass concentration and its uncertainty are traceable to the stated 
value of the mass concentration in United States National Reference Preparation (USNRP) 12-0575C (Reimer et al., 
Am. J. Clin. Pathol. 77 (1982) 12-19) 
3) The certified uncertainty is the expanded uncertainty with a coverage factor k = 2 corresponding to a level of 
confidence of about 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the Expression of Uncertainty 
in Measurement (GUM:1995), ISO, 2008 
 
The minimum sample intake is 10 µL 
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Glossary 
ANCAs 
Anti-MPO 
ANOVA  
Anti-neutrophil cytoplasmic antibodies 
Anti-myeloperoxidase 
Analysis of variance 
b Slope in the equation of linear regression y = a + bx 
c 
cij 
c0i 
Mass concentration c = m / V (mass / volume) 
Concentration of the protein in dilution j of material i 
Concentration of the protein in material i 
canti-MPO IgG 
cERM-DA476/IFCC 
Concentration of the purified anti-MPO IgG 
Concentration of anti-MPO IgG in the ERM-DA476/IFCC 
CLSI Clinical and Laboratory Standards Institute 
CRM 
CR 
Cs 
CT 
df 
Certified Reference Material 
Mass concentration of the protein in the calibrant 
Signals of unknown test samples 
Mass concentration of the protein in the target material 
Degrees of freedom 
EC European Commission 
ELISA 
EQAS 
Enzyme-linked immunosorbent assay 
External Quality Assurance Scheme 
ERM® Trademark of European Reference Materials 
EU 
FR 
European Union 
Dilution factor of the calibrant 
FT Dilution factor of TM 
GUM Guide to the Expression of Uncertainty in Measurements  
HEPES 
HIV 
i 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Human immunodeficiency virus 
Different dilutions of TM 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
IgG Immunoglobulin G 
ISO International Organization for Standardization  
IU International units 
IVD-MD In Vitro Diagnostic - Medical Devices 
JRC-IRMM Joint Research Centre – Institute of Reference Materials and 
Measurements 
j Dilutions of the calibrant 
k Coverage factor 
6 
M 
mintended 
mDD,j 
mDM,i 
mM,i 
mPD,i 
mPR,i 
Molar mass 
Mass intended to be added 
Mass of diluent for dilution j 
Mass of the reconstituted material 
Measured mass of water added 
Mass of the diluent for the predilution 
Mass of the reconstituted material 
MS Mean of squares 
MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
n Number of replicates per unit 
n.c. Not calculated 
PES 
QC 
Polyethersulfone  
Quality Control 
rel 
RM 
Index denoting relative figures (uncertainties etc.) 
Reference Material 
RSD Relative standard deviation 
RT Room Temperature 
R2 Coefficient of determination of the linear regression 
s Standard deviation 
sbb
 Between-unit standard deviation; an additional index "rel" is added when 
appropriate 
sbetween Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SEC 
sijk 
Size Exclusion Chromatography 
Signal of the kth measurement of material i within dilution j 
SS Sum of squares 
swithin Standard deviation within groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
swb Within-unit standard deviation 
T Temperature 
t 
ti 
t  
Time 
Time elapse at time point i 
Mean of all ti 
tα, df Critical t-value for a t-test, with a level of confidence of 1-α and df 
degrees of freedom 
tsl 
ttt 
Chosen shelf life 
Chosen transport time 
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TIU Trypsin inhibitor unit 
TM Target material 
TF Transfer factor 
TRIS Tris(hydroxymethyl)aminomethane 
u Standard uncertainty  
U 
ub 
ubal 
Expanded uncertainty 
Standard uncertainty of the slope 
Standard uncertainty related to the balance; an additional index "rel" is 
added as appropriate 
u*bb  Standard uncertainty related to a maximum between-unit inhomogeneity 
that could be hidden by method repeatability; an additional index "rel" is 
added as appropriate 
ubb Standard uncertainty related to a possible between-unit inhomogeneity;  
an additional index "rel" is added as appropriate 
uc Combined standard uncertainty; an additional index "rel" is added as 
appropriate 
uchar,cal Standard uncertainty of the calibrant characterisation; an additional index 
"rel" is added as appropriate 
uchar  Standard uncertainty of the material characterisation; an additional index 
"rel" is added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index 
"rel" is added as appropriate 
UCRM  
 
Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
uERM-DA470k/IFCC Standard uncertainty of the certified value for ERM-DA470k/IFCC 
u∆ Combined standard uncertainty of measurement result and certified 
value 
ults Standard uncertainty of the long-term stability; an additional index "rel" is 
added as appropriate 
upur Standard uncertainty for the purity of the calibrant; an additional index 
"rel" is added as appropriate 
usts 
 
Standard uncertainty of the short-term stability; an additional index "rel" 
is added as appropriate 
USNRP United States National Reference Preparation 
UV Ultraviolet 
V Volume 
y  Mean of all results of the homogeneity study 
α Significance level 
∆meas Absolute difference between mean measured value and the certified 
value 
8 
νMSwithin 
WG-HAT 
Degrees of freedom of MSwithin 
Working Group – Harmonisation of Autoantibody Tests 
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1. Introduction  
1.1 Background 
Autoimmune antibodies are important analytes in laboratory medicine. The measurement of 
their concentrations is used in routine medical evaluations and in a large number of specific 
indications, and can be performed repeatedly without (major) injury to the patient.  
In 2009 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
formed a new working group with a mandate for the Harmonisation of Autoantibody Tests 
(known as WG-HAT). The detection and quantification of IgG antibodies to autoantigens are 
important for the diagnosis and monitoring of a number of autoimmune diseases. For every 
autoantibody in routine use, there is currently marked diversity in the response of methods 
available for analysis and the materials used for assay calibration.  There are materials 
designated as standards for some of these methods, however they are not fully 
characterised and often used inconsistently. This generates large variability in the analysis 
results (as shown in EQAS results) and a potential delay in the diagnosis and subsequent 
follow-up of the disease.  
The immunoassays used for the measurement of autoimmune antibodies can be sensitive 
and specific, and are convenient in a clinical setting because they give fast results. The 
signal is dependent on a large number of factors such as antibody specificity, reaction 
kinetics and equilibria, multimeric state of the proteins, complex matrix effects, etc. Therefore 
the quantification with immunoassays requires the use of a proper calibrant.  
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) 
requires traceability of calibrants and control materials to reference measurement procedures 
and/or reference materials of higher order. 
A calibrant is required to have an assigned value that is metrologically traceable, and 
accompanied by an uncertainty statement. The stability and homogeneity with respect to the 
certified property must be verified, and the calibrant must be commutable, i.e. resemble the 
patient samples [7]. These attributes are particularly challenging for serum protein calibrants, 
as they form a mixture of interacting proteins with different isoforms and complexes.  
 
1.2 Choice of the material 
One of the type of antibodies selected by IFCC for quantification and standardisation are the 
antibodies against the neutrophil enzyme myeloperoxidase. These antibodies are detected 
as perinuclear anti-neutrophil cytoplasmic antibodies (ANCAs) and represent the 
cornerstones of the diagnosis of small vessel associated vasculitis. Microscopic polyangiitis 
and eosinophilic granulomatosis with polyangiitis are disorders mostly associated with ANCA 
antibodies directed against the naturally occurring myeloperoxidase [8].  
The requirements for a material to be used as a reference material for the calibration of 
immunoassay-based in vitro diagnostic devices or control products for anti-MPO IgG quality 
control are, next to requirements for homogeneity, stability, traceability and commutability: 
10 
 The concentration of the target protein in the final material should be high enough so 
that dilutions of the material can cover the relevant part of the measurement interval 
of the methods.  
 There must be continuity of the measurement results from methods calibrated against 
consecutive reference materials. This is an important issue in clinical chemistry, as 
the use of reference ranges and decision limits requires that measurement results are 
comparable over long time scales. 
According to the data received and analysed, the raw material selected for anti-MPO IgG is 
sufficiently commutable to lead to a considerable reduction of inter-assay variances. 
Therefore it was decided to produce the new material according to procedures described 
below.  
 
1.3 Design of the project 
After a thorough commutability study a plasmapheresis material with a high concentration of 
anti-MPO IgG autoantibodies was selected as the starting material [2]. It was converted into 
serum and processed according to the procedure used for the reference material ERM-
DA470k/IFCC. The procedure consists of a delipidation step followed by the addition of 
preservatives (Section 3.2). The processed serum was then transferred to vials (1 mL serum 
per vial) and lyophilised. The vials were closed under nitrogen with rubber stoppers and 
screw caps and were then stored at -70 °C.  
The homogeneity, short term and long term stability of the material were assessed for anti-
MPO IgG.  
A calibration solution was prepared and characterised to facilitate the characterisation of 
ERM-DA476/IFCC. Anti-MPO IgG was purified from plasmapheresis material by a 
combination of affinity chromatography and size exclusion chromatography. A value for the 
IgG concentration in the calibrant was assigned using 5 routine methods selective for total 
IgG (based on either turbidimetry or nephelometry). The value assignment was performed 
using ERM-DA470k/IFCC as a calibrant. The value obtained by immunoassays was 
consistent with that obtained by UV measurements. 
A value was assigned to the ERM-DA476/IFCC by using the purified anti-MPO IgG calibrant 
spiked into human serum and routine anti-MPO IgG procedures (ELISA, chemiluminescent 
and fluoroenzyme immunoassays). This was achieved using a value transfer protocol that 
can be considered as reference procedure [3]. In the value transfer procedure 6 dilutions of 
the target material were measured in parallel next to 6 dilutions of the calibrant. The 
concentration of the target material was determined against the calibrant solutions (Figure 1). 
The procedure is described in detail in Chapter 6.2. 
The characterisation measurements were either performed under an ISO/IEC 17025 
accreditation or within the scope of an ISO 13485 quality system.  
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Figure 1: Traceability chain 
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2. Participants 
2.1 Provision of raw materials  
       Statens Serum Institute, Amager, DK  
  
2.2 Project management and evaluation 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE (accredited to ISO Guide 34 for production of 
certified reference materials, BELAC No. 268-RM) 
2.3 Processing  
• European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE (accredited to ISO Guide 34 for production of 
certified reference materials, BELAC No. 268-RM) 
• Siemens Healthcare Diagnostics Products GmbH, Marburg, DE  
 
2.4 Homogeneity and stability studies 
INOVA Diagnostics, INC., San Diego, US  
 
2.5 Characterisation 
• AESKU Diagnostics GmbH & Co., Wendelsheim, DE  
• Bio-Rad Laboratories INC., California, US  
• DAKO Denmark, Glostrup, DK  
• EUROIMMUN Medizinische Labordiagnostika AG, Dassow, DE  
• EuroDiagnostica AB, Malmö, SE  
• European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE (accredited to ISO Guide 34 for production of 
certified reference materials, BELAC No. 268-RM) 
• IMMCO Diagnostics, Buffalo, US  
• INOVA Diagnostics, INC., San Diego, US  
• Lund University, Lund, SE  
• Protein Reference Unit, St. Georges Hospital, London, UK (certified to UKAS CPA 
1929) 
• Phadia / Thermo Fisher Scientific, Freiburg, DE  
• Roche Diagnostics GmbH, Penzberg, DE 
• Siemens Healthcare Diagnostics Products GmbH, Marburg, DE  
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3. Material processing and process control 
3.1 Origin of the starting material 
The raw material was a plasmapheresis material collected from patients diagnosed with an 
autoimmune, non-infectious disease, provided by Statens Serum Institute (DK). It was tested 
and found to be negative for Hepatitis B surface antigen, HIV 1&2, HIV antigen and Hepatitis 
C antibodies. 
3.2 Processing and processing control 
3.2.1. Plasma conversion into serum 
An aliquot (1 L) of the plasmapheresis material was thawed and warmed up to 37 °C. A 
1/100 volume of 5 mg/mL protamine sulphate solution (Sigma-Aldrich, DE) was then added 
and the material was stirred for 10 minutes at 37 °C. After incubation for one hour at room  
temperature (RT) the material was then incubated at 4 °C for 40 hours to allow the 
formation of fibrin. The fibrin was then removed by centrifugation at 10000 rpm for 10 min 
whereupon the supernatant was filter sterilized using a 0.22 µm PES filter (Corning 
Incorporated, USA). 
 
3.2.2. Serum processing 
The procedure for the processing of serum was based on that used for ERM-DA470k/IFCC 
[3]. Defibrinated serum was treated with NaCl (final concentration 50 g/L, Sigma-Aldrich, 
DE) and the pH adjusted to 8.5 with a saturated TRIS solution (Sigma-Aldrich, DE). The 
lipids present in the serum were removed by incubation for 1 h at 4 °C under slow stirring 
(100 rpm) with synthetic amorphous silica. Protein precipitates and silica particles were 
removed by centrifugation at 10000 rpm for 30 min. The clear supernatant was dialysed 
against nine changes of isotonic NaCl solution (0.9 % w/v) (Sigma-Aldrich, DE) over 24 
hours. The pH was then adjusted to 7.2 with a 100 mmole/L HEPES solution (Sigma-
Aldrich, DE) and the following preservatives added: sodium azide (final concentration of 
0.95 g/L), aprotinin (final concentration of 61.5 TIU/mL) and benzamidine hydrochloride 
monohydrate (final concentration of 1 mmole/L). All three preservatives were purchased 
from Sigma-Aldrich (DE). The serum was then filter sterilised through a 0.22 µm PES filter 
(Corning Incorporated, USA) prior to dilution 1:6 with Zenalb® 4.5 (Bio Products Laboratory, 
UK). 
 
3.2.3. Filling 
1 mL serum was transferred to each vial under clean-room conditions. Colourless threaded 
siliconised glass vials and white screw caps were used.  
Lyophilisation was started within one hour after filling the vials. Closing the bottles using 
rubber stoppers was performed under a low-pressure nitrogen atmosphere. Filling and 
lyophilisation were carried out with the local defined processes in accordance with LP-00614 
(Filling and Labelling) and LP-00619 (Lyophilisation). 
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4. Homogeneity 
A key requirement for any certified reference material aliquoted into units is the equivalence 
between those units. In this respect, it is relevant whether the variation between units is 
significant compared to the uncertainty of the certified value. Consequently, ISO Guide 34 
requires RM producers to quantify the between unit variation. This aspect is covered in 
between-unit homogeneity studies. 
4.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified value of the CRM 
was valid for all vials of the material, within the stated uncertainty. 
For the between unit homogeneity assessment, the number of units selected corresponds to 
approximately the cubic root of the total number of units produced and therefore 20 units 
were selected using a random stratified sampling scheme, covering the whole batch. For 
this, the batch was divided into twenty groups (with a similar number of units) and one unit 
was selected at random from each one. Three independent samples were taken from each of 
these units, and analysed by an ELISA (QUANTA LiteTM MPO IgG). The measurements were 
performed under repeatability conditions and in a randomised manner so as to be able to 
separate a potential analytical drift from a trend in the filling sequence.  
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. No trends were observed.  
The dataset was assessed for consistency using Grubbs outlier tests with a confidence level 
of 99 % on the individual results and the unit means. No outlying individual results or outlying 
unit means were detected.  
Quantification of between-unit inhomogeneity was undertaken by analysis of variance 
(ANOVA), which separates the between-unit variation (sbb) from the within-unit variation (swb). 
The latter is equivalent to the method repeatability if the individual samples are 
representative for the whole unit.  
Evaluation by ANOVA requires mean values per unit which follow at least a unimodal 
distribution and results for each unit that follow unimodal distributions with approximately the 
same standard deviations. The distribution of the mean values per unit was visually 
assessed using histograms and normal probability plots. Minor deviations from unimodality of 
the individual values do not significantly affect the estimate of between-unit standard 
deviations. The results of the statistical evaluation of the homogeneity studies at a 95 % 
confidence level show that the material is homogeneous. 
It should be noted that sbb,rel and swb,rel are estimates of the true standard deviations and are 
subject to random fluctuations. Therefore, the mean square between groups (MSbetween) can 
be smaller than the mean squares within groups (MSwithin), resulting in negative arguments 
under the square root used for the estimation of the between-unit variation, whereas the true 
variation cannot be lower than zero. In this case, u*bb, the maximum inhomogeneity that could 
be hidden by method repeatability, was calculated as described by Linsinger et al. [9]. u*bb is 
comparable to the limit of detection of an analytical method, yielding the maximum 
inhomogeneity that might be undetected by the given study setup.  
Method repeatability (swb,rel), between–unit standard deviation (sbb,rel) and u*bb,rel were 
calculated as:  
y 
within
rel,wb
MS
s =  Equation 1 
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y
n
MSMS
s
withinbetween
rel,bb
−
=  Equation 2 
y
νn
MS
u
MSwithin
within
*
rel,bb
4
2
=  Equation 3 
MSwithin mean square within a unit from an ANOVA  
MSbetween mean squares between-unit from an ANOVA 
y  mean of all results of the homogeneity study 
n mean number of replicates per unit 
MSwithinν  degrees of freedom of MSwithin  
 
The results from the homogeneity studies are shown in Annex A. The results of the 
evaluation of the between-unit variation are summarised in Table 1. The values from the 
equations above were converted into relative uncertainties. The uncertainty contribution for 
homogeneity was determined by the method repeatability. 
 
Table 1: Results of the homogeneity study 
CRM 
swb,rel 
[%]
 
sbb,rel 
[%]
 
u*bb,rel 
[%] 
ERM-DA476/IFCC 3.09 n.c.(1) 0.85 
 
1)
 n.c.: cannot be calculated as MSbetween < MSwithin 
As u*bb sets the limits of the study to detect inhomogeneity it was adopted as the uncertainty 
contribution to account for potential inhomogeneity. 
 
4.2 Within-unit homogeneity and minimum sample intake 
The minimum sample intake is the minimum amount of sample which is shown to be 
representative for the whole unit and thus can be used in an analysis. The within-unit 
homogeneity is correlated to the minimum sample intake and therefore it follows that 
individual aliquots of a material below the minimum sample intake will not contain the same 
amount of analyte. Sample sizes equal or above the minimum sample intake guarantee the 
certified value within its stated uncertainty.  
The smallest sample intake tested was determined using the method information supplied by 
the participants, from the results of the homogeneity/stability experiments and from the 
characterisation study. In all cases ELISA based methods were used. The smallest sample 
intake used was 10 µL, which was henceforth established as the minimum sample intake.  
The standard deviation within a bottle (swb) is lower than the expected method variability, so 
there is no indication of intrinsic heterogeneity or contamination at a sample intake of 10 µL. 
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5. Stability 
Stability testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the material to the customers (short-term stability). 
During transport, especially in summer time, temperatures up to 60 °C can be reached and 
stability under these conditions must be demonstrated if the material is to be transported at 
ambient temperatures. 
The stability studies were performed using an isochronous design [10]. In this approach, 
units were stored for a specified length of time at different temperature whereupon the units 
were then moved to conditions where further degradation was assumed to be negligible 
(reference conditions). At the end of the isochronous storage, the samples were analysed 
simultaneously under repeatability conditions. Analysis of the material (after various 
exposure times and temperatures) under repeatability conditions greatly improves the 
sensitivity of the stability tests. The data were analysed by calculating the regression line for 
protein concentration in relation to time, and determining whether it is significantly different 
from zero. 
 
5.1 Short-term stability study 
During the short-term stability study, units were stored at -20 °C, 4 °C and 18 °C for 0, 1, 2 
and 4 weeks. The reference temperature was set at -150 °C. Two units per storage time 
were selected using a random stratified sampling scheme. Three samples, taken from each 
unit, were analysed by anti-MPO BioFlash ELISA under repeatability conditions in a 
randomised sequence, to be able to separate a potential analytical drift from a trend over 
storage time. The values were corrected for the variable reconstitution volume.  
The data were evaluated for each temperature individually. The results were screened for 
outliers using the single and double Grubbs test. For every temperature there were 24 
measurements performed.  
Furthermore, the data were evaluated against storage time and regression lines of protein 
concentration versus time were calculated. The slope of the regression line was tested for 
statistical significance (loss/increase due to shipping conditions) and it was found to be 
significantly different from 0 when the absolute value of the slope b divided by its uncertainty 
ub (|b/ub|) is larger than t0.05, 22= 2.07.  There were no indications of instability at any of the 
temperatures for measurements performed with the BioFlash assay.  
Since no technical reason for the outliers was found, all data were retained for statistical 
analysis.  
The results of the short-term stability studies are shown in Annex B.  
No technically unexplained outliers/Statistical outliers were detected and thus all data were 
retained for the estimation of usts. None of the trends were statistically significant at a 95 % 
confidence level for any of the temperatures. 
From this study it was concluded that for the shipment (up to 2 weeks) the possible 
contribution of the transport to the uncertainty of the certified values is negligible compared to 
the overall uncertainty. For practical reasons and for retaining the uncertainty values as low 
as possible it is strongly recommended to ship the material on dry ice and within one week.  
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5.2 Long-term stability study 
During the long-term stability study, samples were stored at -20 °C and -70 °C for 0, 8, 16 
and 24 months. The reference temperature was set at -150 °C. Two units per storage time 
were selected using a random stratified sampling scheme. Three samples from each unit 
were analysed by a BioFlash ELISA immunoassay under repeatability conditions, in a 
random sequence to be able to separate any potential analytical drift from a trend over 
storage time.  
The data were evaluated for each temperature individually. No outliers were found when the 
results were screened using the single and double Grubbs test. Furthermore, the data were 
plotted against storage time and linear regression lines of protein activity (U/mL) fraction 
versus time were calculated. The slope of the regression lines was assessed for statistical 
significance (loss/increase due to storage conditions). The slopes of the regression lines 
were not significantly different from zero (at a 95 % confidence level) for either temperature.  
No technically unexplained outliers were observed and none of the trends was statistically 
significant at a 95 % confidence level for any of the temperatures. The material can be stored 
at both -20°C and -70 °C. However, as it is envisaged to be stored for long periods of time, it 
should be preferably kept at -70 °C.  
 
5.3 Estimation of uncertainties 
Due to the intrinsic variation of measurement results, no study can rule out degradation of 
materials, even in the absence of statistically significant trends. It is therefore necessary to 
quantify the potential degradation that could be hidden by the method repeatability, i.e. to 
estimate the uncertainty of stability. This means, that even under ideal conditions, the 
outcome of a stability study can only report that there was no detectable degradation during 
the timeframe studied.  
Uncertainties of stability during dispatch and storage were estimated as described in [11]. In 
this approach, the uncertainty of the linear regression line with a slope of zero was 
calculated. The uncertainty contributions usts and ults are calculated as the product of the 
chosen transport time/shelf life and the uncertainty of the regression lines as: 
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The following uncertainties were estimated: 
- usts,rel, the uncertainty of degradation during dispatch. This was estimated from the  
-20 °C studies. The uncertainty describes the possible change during a dispatch at  
-20 °C lasting for one week. 
- ults,rel, the stability during storage. This uncertainty contribution was estimated from 
the -70 °C study. The uncertainty contribution describes the possible degradation 
during 24 months storage at -70 °C.  
 
The results of these evaluations are summarised in Table 2. 
 
Table 2: Uncertainties of stability during dispatch and storage. usts,rel was calculated for 
storage at -20 °C for 1 week; ults,rel was calculated for storage at  -70 °C for 2 years. 
CRM usts ,rel [%] 
ults,rel 
[%] 
ERM-DA476/IFCC 0.66 1.95 
 
After the certification study, the material will be included in IRMM's regular stability 
monitoring programme. 
 
6. Characterisation  
The material characterisation is the process of determining the property value of a reference 
material. 
The characterisation of both the anti-MPO IgG serving as calibrant and of the candidate 
CRM was based on an inter-laboratory comparison of expert laboratories, i.e. the protein 
concentration of the material was determined in different laboratories who applied their own 
methodology and instrumentation. This approach aims to negate the laboratory bias, which 
reduces the combined uncertainty.  
In the case of the value assignment for the calibrant, the participant laboratories used 
turbidimetry and nephelometry for their measurements. For the characterisation of the ERM-
DA476/IFCC all participants used ELISA-type immunosorbent assays.  
 
6.1 Selection of participants  
Six laboratories were selected for the calibrant material and 10 for the target material based 
on criteria that comprised both technical competence and quality management. Each 
participant was required to operate a quality system and to deliver documented evidence of 
its laboratory proficiency in the field of in vitro diagnostics in relevant matrices by submitting 
results for intercomparison exercises or method validation reports. Having a formal 
accreditation was not mandatory, but meeting the requirements of ISO/IEC 17025 was. The 
accreditation numbers for the accredited laboratory are stated in the list of participants 
(Section 2). 
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6.2 General principles of the value assignment  
The laboratories were provided with detailed protocols and reporting sheets, as well as with 
vials of the materials to be analysed. Laboratories were asked to specify the platform and 
reagents used, and the order in which the measurements were performed. Both procedures 
required that the material was reconstituted the day before the measurements, according to 
the procedure described in the certificate of ERM-DA470k/IFCC and in the present report 
(Chapter 9.3). 
 
 
Principle of the analysis 
The aim of the value transfer is to determine the transfer factor (TF) 
TF = CT/CR (1) 
where CT and CR are the mass concentration of the protein in the target material (TM, ERM-
DA476/IFCC) and in the calibrant (purified anti-MPO IgG), respectively.  
Six different dilutions of the calibrant are prepared. The mass concentration of the protein in 
each dilution will be: 
CR(i) = FR(i) x CR  (2) 
where FR is the dilution factor of the control and (i) denotes the different dilutions (i = 1 to 6). 
The concentration of the protein in the dilutions of the target material will be: 
CS(j) = FT(j) x CT (3) 
Where FT is the dilution factor of TM and (j) denotes the different dilutions of TM (j = 1 to 6). 
For the transfer procedure a calibration run is made, and the calibration curve is constructed 
by plotting the signals against the different dilutions of RM. In a measurement run the 
different dilutions of TM are assayed. The signals of these unknown test samples CS(j) are 
interpolated on the calibration curve, and are measured in relative concentrations of RM: 
CS(j) = FR(j) x CR (4) 
A combination of (3) and (4) gives: 
CS(j) = FT(j) x CT = FR(j) x CR 
FR(j) = CT/CR x FT(j) (5) 
which is the equation of a straight line through the origin (y = TF x). 
The different dilution factors FR(j) obtained by interpolation are plotted against the different 
dilution factors FT(j) used for the initial dilution of TM. Since all dilutions are controlled by 
weighing, the uncertainty of FT(j) is negligible compared to that of the measurement results. 
 
Calculation of the dilutions 
The precision of the values for the dilutions were considerably improved by weighing all the 
liquids used for the reconstitution of the materials and for the preparation of the dilutions to a 
precision of at least 0.0001 g. 
The following mass corrections were applied: 
For the reconstitution: 
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iM,
intended
iM,
m
mf =  
Where mintended is the mass intended to be added (1.0000 g), and mM,i is the measured mass 
of the water added to the vial 
For eventual predilutions: 
iPD,iPR,
iPR,
iP,
mm
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+
=  
where mPR,i and mPD,i are the masses of the of the reconstituted material and of the diluent for 
the predilution 
 
For the dilutions:  
iDD,iDM,
iDM,
ijD,
mm
mf
+
=  
for the dilution j of the material i, with mDM,i the mass of the reconstituted (eventually 
prediluted) material, and mDD,i the mass of the diluent for dilution j. 
The concentration cij (with c = m / V (mass / volume) and the unit g/L) of the proteins in the 
dilutions is calculated via: 
cij = c0i x fM,i x fP,i x fD,ij  
with c0i of the protein in material i, and cij the concentration of the protein in dilution j of 
material i. 
 
 
Determination of the transfer factors (TFs) 
During the transfer procedure the dilutions of the reference material (either ERM-
DA470k/IFCC in case of the characterisation of the calibrant or of anti-MPO IgG in the case 
of the characterisation of ERM-DA476/IFCC) were used to construct the calibration curve. 
Based on this curve and the known concentration of the spiked material, the values of the 
target material were calculated. The relative concentrations were corrected for the masses of 
the dilutions (and predilution).  
During the value transfer procedure the laboratories measured the 6 dilutions of the target 
(Y1-Y6) and the calibrant (X1-X6) in triplicate on each day. For both materials, single 
measurement results Sijk (signal of the kth measurement of material i within dilution j, in g/L) 
were plotted in scatter plots Sijk = f(cij) so as to evaluate outliers. A linear regression with 
intercept was performed on the means of the Sijk in function of the concentration cij. 
The following analyses were performed on all data: 
-   Evaluation of the studentised residuals for the identification of outliers  
- Test for the homoscedasticity of the residuals (whether the variances are    
homogeneous) via a t-test 
-   Test for normality (visual inspection and normal probability plot) 
-   Test for linearity (visual inspection and evaluation of R2)  
-   Test for outliers of the regression model according to the method of Lund [12] (only 
in case of homoscedasticity)  
-   Verification that the intercept ± 4 times the s covers the origin.  
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The TFs were calculated as the ratio of the slopes of the linear regression lines for the 
candidate reference material and for the calibrant.  
The following general acceptance criteria were applied to the datasets: 
 
1. R2 of the regression must be above 0.99 for data of all platforms  
2. Data from at least 4 dilutions must be available 
3. The dataset from any one day must contain at least 50 % of the data generated. 
on that day, otherwise all of the data generated on that day are declared non-valid 
4. At least two daily value assignments must be valid 
5. The day-to-day variation (RSD) of valid datasets for the protein and laboratory 
must be below 15 %   
Rationale for the acceptance criteria: 
- Overall R2 < 0.99 of regression indicates quality problems in the measurements (scattering, 
outliers, run-to-run variation).   
 
- During the data analysis, the results where the linear regression went through 0 (y = bx) 
were compared to those when linear regressions were performed with an intercept  
(y = a+bx). The mean of means of the TFs between laboratories were comparable. However, 
since only measured data were used and no model other than the linearity within the actual 
measurement interval was assumed it was decided to process the data allowing for 
intercepts in the linear regression, provided that the intercept ± 4 s covers the origin. As a 
consequence, the criterion for the acceptance of datasets was adapted, and a (within 
laboratory) day-to-day RSD of 15 % was defined.  
 
6.3 Characterisation of the calibrant 
During the characterisation of the calibrant (anti-MPO IgG), each laboratory received one vial 
of purified anti-MPO IgG and five vials of its dilution prepared in JRC-IRMM as well as one 
vial of ERM-DA470k/IFCC and five vials of its dilution. They were required to provide 18 
independent results, per material (three per dilution). Participating laboratories were 
instructed to use their in-house calibrant to determine the dose-response function of the 
instrument. The units for material characterisation were selected using a random stratified 
sampling scheme and covered the whole batch. The techniques used to measure the protein 
concentration of the calibrant were nephelometry, turbidimetry and spectrophotometry. The 
measurements were performed with different platforms (Annex C, Table C1) and reagents. In 
total six laboratories participated in the characterisation study. 
 
6.3.1. Production and physico-chemical characterisation of the calibrant 
 
The anti-MPO IgG was purified from human serum (provided by Statens Serum Institute) in a 
three step purification process. Firstly, total IgG was separated by affinity chromatography 
using a Protein A column. Secondly, the specific anti-MPO IgG was separated from all other 
IgGs eluting from the protein A column using an in-house prepared Hi-trap column prepared 
using commercially available purified human myeloperoxidase (Scipac, UK) according to the 
protocol provided by the manufacturer. All anti-MPO IgG containing fractions were pooled, 
concentrated to a final volume of 500 µL using Amicon Ultra centricons with a 30 KDa cut-off 
(Milipore, USA) and subsequently applied on a Superdex 200 10/300 GL column (GE 
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Healthcare, SE). The purity of the final material with respect to IgG selectivity for MPO was 
assessed by affinity chromatography. The in-house prepared anti-MPO Hi-Trap column 
described above was used for this purpose. In the chromatograph only one peak was eluted 
under the acidic conditions of the eluting buffer (pH 2.7) and no peaks were observed during 
the elution with the binding buffer (pH 7.0). The background noise was taken into 
consideration for the ratio to the peak for anti-MPO IgG. The uncertainty of the purity of the 
material was set as three times this ratio. The calculated uncertainty was equal to 0.5 % 
(Table 3). 
 
6.3.2. Value assignment of the calibrant 
 
The concentration of the calibrant was measured by nephelometry or turbidimetry (Annex C, 
Table C1). The participating laboratories provided us with concentration values for both the 
ERM-DA470k/IFCC and the purified anti-MPO IgG solution based on their in-house calibrant. 
Regression lines were constructed comparing these measured concentrations to the 
gravimetrically calculated dilution factors of these samples. The slope ratio of the ERM-
DA470k/IFCC to the purified anti-MPO IgG was used to determine the value of the dilutions 
of the target material. 
 
The data were assessed for both their compliance with the analysis protocol and for their 
validity based on technical reasons. The following criteria were considered during the 
evaluation:  
- Compliance with the analysis protocol: sample preparations and measurements 
performed on a minimum of two days, and the analytical sequence. 
- Method performance, i.e. agreement of the measurement results with the assigned 
value of their in-house QC sample. 
- R2 of the regressions must be above 0.99 for data of all platforms.  
 
Based on the criteria above, one dataset was rejected as not technically valid. The results 
provided from this laboratory did not comply with the criteria for the correlation coefficients, 
showing R2 values < 0.99. In another laboratory (L1, Annex C, Table C1), the higher 
concentration analysed was not taken into account while plotting the results as it was outside 
the laboratory's working range of the method. 
 
The 5 datasets accepted based on technical reasons were assessed for the normal 
distribution of dataset means using normal probability plots and were assessed for outlying 
means using the Grubbs test and using the Cochran test for outlying standard deviations 
(both at a 99 % confidence level). Standard deviations within (swithin) and between (sbetween) 
laboratories were calculated using one-way ANOVA.  
The results of the individual laboratories are given in Table C1 of the Annex C. 
The uncertainty relating to the characterisation of the calibrant (purified anti-MPO IgG) was 
estimated as the standard error of the mean of laboratory means (Table 3). The uncertainty 
of the reference material used for the calibration (ERM-DA470k/IFCC) was taken into 
account as well the uncertainty of the purification of the material. The uncertainty deriving 
from the gravimetric preparation of the dilutions was found to be very low and according to 
GUM specifications it was not taken into account for the final uncertainty of the calibrant 
(ubal,rel = 0.005 %).  
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Table 3: Uncertainty budget for purified anti-MPO IgG.  
Analyte p Mean concentration [mg/mL] 
s 
[mg/mL] 
uERM-DA470k,rel 
[%] 
uchar, cal rel 
[%] 
upur,rel 
[%] 
anti-MPO 
IgG 5 1.52 0.03 0.98 0.88 0.43 
 
These different contributions were combined to estimate the relative uncertainty of the 
concentration value of the calibrant (uanti-MPO IgG, rel) as:  
2
rel pur,
2
CDA470k/IFC-ERM
2
rel cal, charIgG  MPO-anti uuuu ++=  Equation 6 
- uchar,cal was estimated from the data in Annex C, Table C1.  
- uERM-DA470k/IFCC was estimated in the report of the material [3] 
- upur was estimated as described in Section 6.3.1. 
 
The concentration of the material was additionally determined by UV spectrophotometry at 
280 nm using an absorption coefficient of 1.36 (g/L)-1cm-1 (210000 M-1cm-1) [13]. The 
concentration which was measured on 4 separate days, in triplicate, was equal to 1.43 
mg/mL. This value was not used for the calculation of the certified value of the candidate 
reference material nor in the calculation of the uncertainties. 
 
6.4 Characterisation of ERM-DA476/IFCC 
 
During the target material characterisation each laboratory received four vials of ERM-
DA476/IFCC and four vials of anti-MPO spiked into human serum. They were required to 
perform six dilutions from these vials and to provide 72 independent results, three per vial 
per day, for each material. The vials for the materials characterisation were selected using a 
random stratified sampling scheme and covered the whole batch. The sample preparations 
and measurements had to be spread over four days to ensure intermediate precision 
conditions. For the spiked material (calibrant), participants were required to treat them as 
they would any other sample. The dilution protocol was the same for both materials (6.67, 
10, 15, 20, 50 and 100 (m/m) % of the reconstituted materials). 
The techniques used to measure the protein concentration were traditional ELISAs and in 
some cases its variations (chemiluminescent and fluoroenzyme immunoassays) specific for 
IgG anti-MPO. In total 10 laboratories participated in the value assignment, using 9 different 
kits (Annex C, Table C2). 
 
The data were first assessed for compliance with the requested analysis protocol and for 
their validity based on technical reasons. The following criteria were considered during the 
evaluation:  
- Compliance with the analysis protocol (sample preparations and measurements 
performed on a minimum of two days) and the analytical sequence. 
- Method performance, i.e. agreement of the measurement results with the assigned 
value of their in-house QC sample 
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- R2 of the regressions either linear or logarithmic must be above 0.99 for data of all 
platforms  
 
Linear regressions were used for the analyses of the data provided by laboratories 1, 3, 5-10 
(Annex C, Table C2). However, in the case of laboratories 2 and 4 the data provided were 
following a logarithmic distribution and had to therefore be treated accordingly.  
Based on the above criteria, the results obtained from laboratory 10 were completely omitted 
and not used for the certification. In particular, the R2 values for all days were much below 
the set limit of 0.99 whilst at the same time there was a 35 % day-to-day variation. 
Additionally for laboratory 3, two out of 4 days had correlation coefficients below 0.99 and 
thus those two days were not taken into account for the final value assignment.  
The valid datasets were assessed for the normal distribution of the dataset means using 
normal probability plots and were assessed for outlying means using the Grubbs test and 
using the Cochran test for outlying standard deviations (both at a 99 % confidence level). 
Standard deviations within (swithin) and between (sbetween) laboratories were calculated using 
one-way ANOVA.  
The laboratory means follow normal distributions. None of the data contains outlying means 
and variances. The datasets were therefore consistent and the mean of laboratory means 
was a good estimate of the true value. The value assignment data of the individual 
laboratories are shown in Annex C, Table C3. 
7. Uncertainty budget and certified values 
Certified values are values that fulfil the highest standards of accuracy. Procedures at IRMM 
require no less than 6 valid datasets to assign certified values. Full uncertainty budgets in 
accordance with the 'Guide to the Expression of Uncertainty in Measurement' [6] were 
established. A certified value was assigned to ERM-DA476/IFCC. 
 
The assigned uncertainty consists of uncertainties relating to the characterisation of the 
target material, uchar (Section 6), to the combined uncertainty of the characterisation of the 
calibrant uchar,cal (Section 6), to the potential between-unit inhomogeneity, ubb (Section 4) and 
to the potential degradation during transport (usts) and long-term storage, ults (Section 5). The 
uncertainty relating to the use of analytical balance during the gravimetric preparation of the 
dilutions of both the calibrant and the target material was found to be negligible (equal to 
0.005 and 0.006 % respectively) [4]. The uncertainty relating to possible degradation during 
transport and long-term storage is included in the results for usts and ults. The uncertainty of 
between-unit inhomogeneity was found to be too low to be calculated and thus the maximum 
hidden heterogeneity was eventually used for the calculation of the uncertainty of the 
certified value. These different contributions were combined to estimate the expanded, 
relative uncertainty of the certified value (UCRM, rel) with a coverage factor k as:  
 
2
rel lts,
2
rel sts,
2
rel bb,
2
rel cal, char,
2
rel char,rel CRM, uuuuukU ++++⋅=  Equation 7 
 
- uchar was estimated as described in Section 7.1  
- uchar,cal was estimated as described in Section 6.3.2 
- ubb was estimated as described in Section 4.1. 
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- usts was estimated as described in section 5.3 
- ults was estimated as described in Section 5.3.  
 
7.1 Certified value 
 
The certified value was calculated from the average of the TF (Annex C, Table C3) and the 
value of the calibrant (Table 3, 3rd column) according to: 
cERM-DA476/IFCC = TFaverage * canti-MPO IgG 
Where canti-MPO IgG is the concentration of anti-MPO IgG (calibrant) spiked gravimetrically into 
human serum. 
The uncertainty related to the characterisation of the ERM-DA476/IFCC is estimated as the 
standard error of the mean of laboratory means (Table 4). 
 
Table 4: Value assignment for ERM-DA476/IFCC 
CRM p Mean [mg/L] s [mg/L] uchar, rel  [%] 
ERM-DA476/IFCC 9 84.20 10.69 4.25 
 
7.2 Estimation of uncertainty 
 
The relative expanded uncertainty was calculated from the relative combined standard 
uncertainty uCRM,rel by multiplication with a coverage factor k (UCRM=uCRM*k). This coverage 
factor was taken as 2 as there is a sufficient numbers of degrees of freedom of the different 
uncertainty contributions. The relative expanded uncertainty was multiplied by the mean of 
dataset means to obtain the expanded uncertainty UCRM. 
The uncertainty budget after taking into consideration the various uncertainty contributions 
and the relative combined uncertainty (uCRM,rel) is shown in Table 5. 
 
Table 5: Uncertainty budget for ERM-DA476/IFCC 
CRM  uanti-MPO IgG rel  [%] uchar, rel [%] 
ubb, rel 
[%] 
usts, rel 
[%] 
ults, rel 
[%] 
uCRM,rel 
[%] 
UCRM 
[mg/L] 
ERM-DA476/IFCC 1.38 4.25 0.84 0.66 1.95 4.99 8.40 
 
Finally the certified value for the ERM-DA476/IFCC is equal to 84 mg/L and the expanded 
uncertainty of this value is equal to 9 mg/L. 
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8. Metrological traceability and commutability 
8.1 Metrological traceability  
 
Identity 
The mass concentration of anti-MPO IgG in ERM-DA476/IFCC is defined by the 
immunoassay procedures used to characterise it. The assigned value is therefore 
operationally defined by method. 
 
Quantity value 
The measurements of anti-MPO IgG were calibrated with ERM-DA470k/IFCC by applying 
the value transfer procedure described in this report. The value transfer measurements were 
strictly controlled with respect to adherence to the procedure and the adequate functioning of 
equipment and reagents was verified. Different combinations of reagents and platforms were 
used, which gave consistent results. Therefore the certified value is not dependent on the 
individual methods.  
The certified values for anti-MPO IgG in ERM-DA476/IFCC were obtained by calibration with 
purified anti-MPO. 
The traceability chain is based on the use of calibrated balances and a thorough control of 
the weighing procedure. The certified mass concentration and its uncertainty are traceable to 
the stated value of the mass concentration in USNRP 12-0575C [14] applying the procedures 
described in the certification report of ERM-DA470k/IFCC [3] and in the present report. 
8.2 Commutability 
Many measurement procedures include one or more steps, which select specific analytes 
from the sample for the subsequent steps of the measurement process. It is difficult to mimic 
all the analytically relevant properties of real samples within a CRM. The degree of 
equivalence in the analytical behaviour of real samples and a CRM with respect to various 
measurement procedures (methods) is summarised in a concept called 'commutability of a 
reference material'. There are various definitions expressing this concept. For instance, the 
CSLI Guideline C-53A [7] recommends the use of the following definition for the term 
commutability: 
"The equivalence of the mathematical relationships among the results of different 
measurement procedures for an RM and for representative samples of the type intended 
to be measured." 
The commutability of a CRM defines its fitness for use and, thus, is a crucial characteristic for 
the application of different measurement methods. When commutability of a CRM is not 
established in such cases, the results from routinely used methods cannot be legitimately 
compared with the certified value to determine whether a bias does not exist in calibration, 
nor can the CRM be used as a calibrant. For instance, CRMs intended to be used to 
establish or verify metrological traceability of routine clinical measurement procedures must 
be commutable for the routine clinical measurement procedures for which they are intended 
to be used. 
Different formats of candidate reference materials, all based on the same raw material as 
ERM-DA476/IFCC, have been tested and found to be commutable for combinations of seven 
methods giving correlating results (Annex D, Table D1). Therefore ERM-DA476/IFCC is 
expected to be commutable for the majority of IgG anti-MPO methods [2]. However, if 
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another method is used other than those included here then commutability should be 
verified. 
 
9. Instructions for use 
9.1 Safety information 
The usual laboratory safety measures apply. Do not discharge the waste into the drain. Each 
portion of donated blood used in the production of the material has been tested and found 
negative for Hepatitis B surface antigen, HIV 1&2, HIV antigen and Hepatitis C antibodies. 
However, the product must be handled with adequate care as any material of human origin. 
It is intended for in vitro analysis only. 
 
9.2 Storage conditions 
Unopened vials should be stored at both -20°C and -70 °C. However, as it is envisaged to be 
stored for long periods of time, it should be preferably kept at -70 °C. If microbial 
contamination has been excluded during the reconstitution procedure, the solution of ERM-
DA476/IFCC can be used for one week. It is advisable to cover the vial with the original seal 
after use and to store it at 2 to 8 °C.  
Please note that the European Commission cannot be held responsible for changes that 
happen during storage of the material at the customer's premises. 
9.3 Preparation and use of the material/Reconstitution 
The material must be reconstituted according to the following procedure: 
• Remove the vial from the freezer or refrigerator during the afternoon of the day before 
use and place the vial in the room where the balance is located for 1 hour. 
• After 1 hour, tap the bottom of the vial gently on the surface of the table. Make sure that 
all the material has settled down on the bottom of the vial. Remove the screw cap. 
• Weigh the vial together with the rubber stopper. Note the mass or press the “TARE” 
button on the balance. Lift the rubber stopper with care until air is allowed to enter the vial 
and the groove in the rubber stopper becomes accessible. 
• Add 1.00 mL of water through the groove, and press the rubber stopper back into place. 
Weigh the vial and note the mass. If you have used the “TARE” function, the value can 
be used directly for the mass m. Otherwise the first mass must be subtracted from the 
second to obtain m. 
• The concentration of a particular protein in the solution, corrected for the reconstitution 
mass, can be obtained by multiplying the certified value for that protein with mintended / m, 
with mintended the mass intended to be added (1.000 g).  
• Leave the vial at room temperature for one hour, then invert it carefully at least five times 
(do not shake it) during the next hour. 
• Leave the vial at room temperature overnight. On the day of use invert the vial carefully 
five times during one hour before use. 
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9.4 Minimum sample intake 
The minimum representative sample intake is 10 µL. The entire content of the vial must be 
reconstituted. 
9.5 Use of the certified value 
The main purpose of this material is to be used for the calibration of immunoassay-based in 
vitro diagnostic devices or control products for anti-MPO IgG. As any reference material, it 
can also be used for control charts or validation studies. 
When the material is used as a calibrant in a particular assay the commutability should be 
verified for the assay concerned.  
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, www.erm-crm.org [15].  
For assessing the method performance, the measured values of the CRMs are compared 
with the certified values. The procedure is described here in brief:  
- Calculate the absolute difference between mean measured value and the certified 
value (∆meas). 
- Combine measurement uncertainty (umeas) with the uncertainty of the  
certified value (uCRM): 22 CRMmeas uuu +=∆  
- Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 
95 % 
- If ∆meas ≤ U∆ no significant difference between the measurement result and the 
certified value, at a confidence level of about 95 % exists. 
 
 
Use in quality control charts 
The materials can be used for quality control charts. Different CRM-units will give the same 
result as inhomogeneity was included in the uncertainties of the certified values.  
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Annexes 
Annex A: Results of the homogeneity measurements 
 
Source of 
Variation SS df MS s F 
F-crit 
95 % 
F-crit 
99 % 
Between 
Units 37.6 19 1.98 MSB<MSW 0.67 1.9 2.4 
Within Units 118.3 40 2.96 1.72 
   
Total 155.88 59 
     
Homogeneity 
Results 
Weight.Avg. 
[mg/L] Sbb [mg/L] Sbb  [%] Swb [mg/L] 
Swb  
[%] 
Ubb* 
[mg/L] ubb*[%] 
 
55.76 MSB<MSW MSB<MSW 1.72 3.08 0.47 0.84 
 
Table A1: Analysis of Variance of the homogeneity results 
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Annex B: Results of the short-term stability measurements 
 
Fig. B1: Short-term stability data (results of individual replicates) of ERM-DA476/IFCC; 
Measured values by an ELISA immunoassay (U/mL), when stored for several weeks at -20 
°C (a), 4 °C (b) and 18 °C (c), results at time point 0 weeks correspond to units that were 
stored at the reference temperature of -20 °C. 
 
CRM usts, 1 week [%] usts, 2 weeks [%] 
ERM-DA476/IFCC 
-20 °C 4 °C 18 °C -20 °C 4 °C 18 °C 
0.66 0.54 0.55 1.32 1.07 1.09 
 
Table B1: Uncertainties of stability during storage at different temperatures for 1 and 2 
weeks 
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Annex C: Calibrant characterisation 
 
anti-MPO IgG 
Laboratory Platform Method Concentration [mg/mL] 
L1 Immage Nephelometry 1.47 
L2 Cobas 6000/8000 Turbidimetry 1.51 
L3 BN Prospec Nephelometry 1.53 
L4 Modular P Turbidimetry 1.55 
L5 Cobas c 501 Turbidimetry 1.52 
 
Table C1: All laboratories giving acceptable results, together with the platforms they used 
and the principles of the methods that these platforms employ are listed.  
 
ERM-DA476/IFCC 
Laboratory Method Principle 
Concentration 
[mg/L] 
L1 Wieslab
®
 Capture 
MPO-ANCA ELISA 92 
L2 ImmuLisa ™ ELISA 68 
L3 
Autoimmune EIA 
Anti-
Myeloperoxidase 
ELISA 99 
L4 
Anti-
Myeloperoxidase 
ELISA (IgG) 
ELISA 75 
L5 Wieslab
®
 Capture 
MPO-ANCA ELISA 88 
L6 Wieslab
®
 MPO-
ANCA ELISA 73 
L7 QUANTA Flash MPO Chemiluminescent immunoassay 78 
L8 EliA MPOS Fluoro-enzyme immunoassay 93 
L9 AESKULISA MPO ELISA 91 
L10 QUANTA Lite
TM MPO 
IgG ELISA - 
 
Table C2: All laboratories participating in the value assignment of the target material. The 
methods they used and the principles that these methods employ are listed. On the last 
column the average concentrations of the ERM-DA476/IFCC are presented.  
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ERM-DA476/IFCC 
Laboratory  
code 
Day 1 
[slope 
ratio] 
Day 2 
[slope 
ratio] 
Day 3 
[slope 
ratio] 
Day 4 
[slope 
ratio] 
TF 
[mean 
slope 
ratio] 
Day-to-
Day 
variation 
[%] 
L1 0.962 0.860 0.827 0.809 0.864 7.91 
L2 0.70 0.63 0.61 0.61 0.639 6.37 
L3 1) 0.918  1) 0.941 0.930 1.75 
L4 0.751 0.697 0.660 0.721 0.707 5.46 
L5 0.723 0.866  1) 0.857 0.815 9.82 
L6 0.674 0.728 0.712 0.589 0.676 9.19 
L7 0.720 0.622 0.738 0.785 0.717 9.60 
L8 no data 0.812 0.889 0.866 0.856 10.69 
L9 0.747 0.771 0.898 0.925 0.835 10.69 
1): results excluded for technical reasons 
 
Table C3: Individual results for the value assignment for the characterisation of the target 
material, ERM-DA476/IFCC. The relative uncertainties per laboratory and their day-to-day 
variation are presented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
 
Annex D: Commutability 
 
Laboratory Method Principle 
L1 Varelisa™ MPO ANCA ELISA 
L2 EliA MPOS Fluoro-enzyme immunoassay 
L3 Wieslab® Capture MPO-ANCA ELISA 
L4 Wieslab® Anti-MPO ELISA ELISA 
L5 Anti-MPO ELISA ELISA 
L6 QUANTA Lite MPO IgG ELISA ELISA 
L7 Anti-MPO ORG 519 ELISA 
 
Table D1: Laboratories that participated in the commutability studies and the methods they 
used 
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